SyntheticMR initiates the listing process for NASDAQ OMX
The Board of SyntheticMR has decided to start the process regarding change of trading venue for the company's shares from Aktietorget to NASDAQ OMX Stockholm. The company's ambition is to complete the change of list in the latter part of 2019.
A listing on NASDAQ OMX is assessed by the Board to strengthen the quality mark for SyntheticMR and to create greater interest in the company's share. In addition, listing should increase trust from global customers and stakeholders.
"Since SyntheticMR was listed on Aktietorget, much has been achieved in the company. We have signed several partnership agreements with the largest MRI manufacturers in the world and the company's software has begun an excting journey to be established on the global market, "says Stefan Tell, CEO.
For further information, please contact Fredrik Jeppsson, CFO and Head of Investor Relations SyntheticMR AB, +46 72 303 13 39 or Stefan Tell, CEO SyntheticMR AB, +46 73 373 40 90.
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI® delivering multiple,
adjustable contrast images and quantitative data from a single 5-6-minute scan – generating increased patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the AktieTorget exchange in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com
This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 25 2018.